BioMed is a developer of tumor immunotherapy drugs. Its core direction is to develop innovative pharmaceutical preparations for tumor immunotherapy, which are expected to synergize with existing clinical tumor treatment technologies and significantly enhance their efficacy. At the same time, the company is still targeting Research and development of new interventional therapy technology for tumors and new cross-biological barrier macromolecule carrier technology. Recently, led by Gongshan Fund, Shanfeng Fund and the Science and Technology Innovation Fund of the park have completed the capital increase of Suzhou Baimai Biomedical Co., Ltd. The financing will be used to promote the company’s pipeline research and development and technology platform construction, helping the company become an international leading biomedical technology platform company.
This article is transferred from: https://www.itjuzi.com/investevent/13695835
This site is only for collection, and the copyright belongs to the original author.